Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

897
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
897
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

511
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
511
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

470
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
470
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

681
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
681
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

504
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
504
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

492
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
492

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Advanced Mobile Laboratory to enable field-based microbial ecology and cell biology across scales.

bioRxiv : the preprint server for biology·2026
Same author

Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function.

Oncogene·2026
Same author

Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial.

EClinicalMedicine·2026
Same author

<i>Bacteroidetes</i> promote hepatocellular carcinoma progression and resistance to immunotherapy.

bioRxiv : the preprint server for biology·2025
Same author

A dynamical measure of the black hole mass in a quasar 11 billion years ago.

Nature·2024
Same author

Predictors of women's attendance in a home-based adapted physical activity program during localized breast cancer treatment.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2022

Related Experiment Video

Updated: Feb 18, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.6K

[Pulmonary tumor thrombotic microangiopathy].

M Merad1, A Alibay1, S Ammari2

  • 1Service d'urgence en oncologie médicale, Gustave-Roussy Cancer Campus Grand Paris, Villejuif, 94805 Villejuif cedex, France.

Revue Des Maladies Respiratoires
|November 21, 2017
PubMed
Summary

Pulmonary tumor thrombotic microangiopathy is a rare syndrome where tumor cells cause lung microvascular damage, leading to heart and respiratory failure. Early diagnosis is challenging, but chemotherapy may offer survival benefits.

Keywords:
CancerEmbolie pulmonaire tumoraleHypertension artérielle pulmonaireMicroangiopathie thrombotique tumorale pulmonairePulmonary hypertensionPulmonary tumor thrombotic microangiopathyTumor pulmonary embolism

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K

Related Experiment Videos

Last Updated: Feb 18, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.6K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Medicine
  • Oncology

Background:

  • Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare clinicopathological syndrome.
  • It involves tumor cell micro-emboli in pulmonary circulation, causing thrombotic microangiopathy.
  • PTTM can lead to respiratory failure and acute or sub-acute right heart failure.

Observation:

  • Histological findings include micro tumor emboli in lung vasculature.
  • Thrombus formation and intimal proliferation are associated with these emboli.
  • Diagnosis before death is extremely difficult, with most data from autopsies.

Findings:

  • Rare pre-mortem diagnoses suggest potential chemotherapy effectiveness.
  • The syndrome's pathophysiology and clinical course require further elucidation.
  • Interdisciplinary research is crucial for understanding PTTM.

Implications:

  • Targeted therapies may improve the prognosis of PTTM.
  • Improved understanding could lead to longer survival, potentially weeks or months.
  • Enhanced collaboration between pathologists and clinicians is essential for advancing PTTM research.